{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:51:57Z","timestamp":1777553517604,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19fk0108085j0001"],"award-info":[{"award-number":["19fk0108085j0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the endgame of global polio eradication, serosurveillance is essential to monitor each country\u2019s vulnerability to poliomyelitis outbreaks. Previously, we developed pseudovirus poliovirus (PV) neutralization test (pPNT) with type 1, 2, and 3 PV pseudovirus (PV<jats:sub>pv<\/jats:sub>), which possess a luciferase-encoding PV replicon in the capsids of wild-type strains (PV<jats:sub>pv<\/jats:sub>[WT]), showing that pPNT with type 2 and 3 PV<jats:sub>pv<\/jats:sub>(WT) but not type 1 shows high correlation with the conventional PV neutralization test (cPNT) performed with vaccine strains. Here, we analyse the antigenicity of PV<jats:sub>pv<\/jats:sub>(WT) and PV<jats:sub>pv<\/jats:sub> with capsid proteins of Sabin vaccine strains (PV<jats:sub>pv<\/jats:sub>[Sabin]) in human serum. Type 2 and 3 PV<jats:sub>pv<\/jats:sub>(WT) and PV<jats:sub>pv<\/jats:sub>(Sabin) show similar antigenicity in the analysed set of human sera in contrast to type 1 PV<jats:sub>pv<\/jats:sub>. The levels of PV<jats:sub>pv<\/jats:sub>(Sabin) infection (%), including about 70% of PV<jats:sub>pv<\/jats:sub> infection (%) measured in the presence of human serum diluted to the cPNT titre, serve as the optimal threshold values for pPNT (5% for type 1 and 2, 10% for type 3) to show high correlation with cPNT results. Our results suggest that pPNT with PV<jats:sub>pv<\/jats:sub>(Sabin) could serve as an alternative to cPNT and provide a rationale for pPNT threshold values.<\/jats:p>","DOI":"10.1038\/s41598-019-48534-1","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T10:03:05Z","timestamp":1566208985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-6626","authenticated-orcid":false,"given":"Minetaro","family":"Arita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masae","family":"Iwai-Itamochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"48534_CR1","first-page":"339","volume":"60","author":"D Bodian","year":"1954","unstructured":"Bodian, D. Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and of low invasiveness. Am. J. Hyg. 60, 339\u2013357 (1954).","journal-title":"Am. J. Hyg."},{"key":"48534_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/0002-9343(49)90130-8","volume":"6","author":"D Bodian","year":"1949","unstructured":"Bodian, D. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 6, 563\u2013578 (1949).","journal-title":"Am. J. Med."},{"key":"48534_CR3","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1099\/0022-1317-70-11-2907","volume":"70","author":"T Couderc","year":"1989","unstructured":"Couderc, T. et al. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 70, 2907\u20132918 (1989).","journal-title":"J. Gen. Virol."},{"key":"48534_CR4","unstructured":"World Health Organization. Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunization. WHO publication no. WHO\/BLG\/95.1. World Health Organization, Geneva (1995)."},{"issue":"3","key":"48534_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/00365540701596003","volume":"40","author":"Masae Iwai","year":"2008","unstructured":"Iwai, M. et al. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand. J. Infect. Dis. 40, 247\u2013253, https:\/\/doi.org\/10.1080\/00365540701596003 (2008).","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"48534_CR6","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","volume":"34","author":"H Shimizu","year":"2016","unstructured":"Shimizu, H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 34, 1975\u20131985, https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.015 (2016).","journal-title":"Vaccine"},{"key":"48534_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.trivac.2015.08.001","volume":"4","author":"S Resik","year":"2015","unstructured":"Resik, S. et al. Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol. 4, 71\u201374, https:\/\/doi.org\/10.1016\/j.trivac.2015.08.001 (2015).","journal-title":"Trials Vaccinol."},{"issue":"5","key":"48534_CR8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1080\/21645515.2019.1572408","volume":"15","author":"Chiemi Hotta","year":"2019","unstructured":"Hotta, C., Ogawa, T. & Shirasawa, H. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hum. Vaccin. Immunother., https:\/\/doi.org\/10.1080\/21645515.2019.1572408 (2019).","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"48534_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.7883\/yoken.JJID.2018.314","volume":"72","author":"T Nakayama","year":"2019","unstructured":"Nakayama, T., Suga, S., Okada, K. & Okabe, N. Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV). Jpn. J. Infect. Dis. 72, 49\u201352, https:\/\/doi.org\/10.7883\/yoken.JJID.2018.314 (2019).","journal-title":"Jpn. J. Infect. Dis."},{"key":"48534_CR10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.vaccine.2019.02.034","volume":"37","author":"H Satoh","year":"2019","unstructured":"Satoh, H. et al. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Vaccine 37, 1964\u20131971, https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.034 (2019).","journal-title":"Vaccine"},{"key":"48534_CR11","unstructured":"WHO http:\/\/www.polioeradication.org\/Portals\/0\/Document\/Resources\/PostEradication\/GAPIII_2014.pdf."},{"key":"48534_CR12","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1099\/vir.0.82172-0","volume":"87","author":"M Arita","year":"2006","unstructured":"Arita, M., Nagata, N., Sata, T., Miyamura, T. & Shimizu, H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 87, 3317\u20133327, https:\/\/doi.org\/10.1099\/vir.0.82172-0 (2006).","journal-title":"J. Gen. Virol."},{"key":"48534_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1021\/acsinfecdis.9b00038","volume":"5","author":"M Arita","year":"2019","unstructured":"Arita, M. & Bigay, J. Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III beta\/Oxysterol-Binding Protein Family I Pathway. ACS Infect. Dis. 5, 962\u2013973, https:\/\/doi.org\/10.1021\/acsinfecdis.9b00038 (2019).","journal-title":"ACS Infect. Dis."},{"key":"48534_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/infdis\/jix556","volume":"217","author":"EB Brickley","year":"2018","unstructured":"Brickley, E. B. et al. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J. Infect. Dis. 217, 371\u2013380, https:\/\/doi.org\/10.1093\/infdis\/jix556 (2018).","journal-title":"J. Infect. Dis."},{"key":"48534_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jix584","volume":"217","author":"AW Rimoin","year":"2018","unstructured":"Rimoin, A. W. et al. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J. Infect. Dis. 217, 223\u2013231, https:\/\/doi.org\/10.1093\/infdis\/jix584 (2018).","journal-title":"J. Infect. Dis."},{"key":"48534_CR16","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jmv.20732","volume":"78","author":"S Fukushi","year":"2006","unstructured":"Fukushi, S. et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol. 78, 1509\u20131512, https:\/\/doi.org\/10.1002\/jmv.20732 (2006).","journal-title":"J. Med. Virol."},{"issue":"1","key":"48534_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.virol.2004.05.017","volume":"326","author":"Dong P Han","year":"2004","unstructured":"Han, D. P., Kim, H. G., Kim, Y. B., Poon, L. L. & Cho, M. W. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 326, 140\u2013149, https:\/\/doi.org\/10.1016\/j.virol.2004.05.017, S0042682204003678 [pii] (2004).","journal-title":"Virology"},{"issue":"9","key":"48534_CR18","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","volume":"89","author":"E. Wright","year":"2008","unstructured":"Wright, E. et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J. Gen. Virol. 89, 2204-2213, https:\/\/doi.org\/10.1099\/vir.0.2008\/000349-0 (2008).","journal-title":"Journal of General Virology"},{"key":"48534_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2009.02.025","volume":"160","author":"A Tamin","year":"2009","unstructured":"Tamin, A. et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods 160, 1\u20136, https:\/\/doi.org\/10.1016\/j.jviromet.2009.02.025 (2009).","journal-title":"J. Virol. Methods"},{"key":"48534_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jviromet.2008.07.015","volume":"153","author":"W Wang","year":"2008","unstructured":"Wang, W. et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods 153, 111\u2013119, https:\/\/doi.org\/10.1016\/j.jviromet.2008.07.015 (2008).","journal-title":"J. Virol. Methods"},{"key":"48534_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1128\/CVI.05225-11","volume":"18","author":"M Arita","year":"2011","unstructured":"Arita, M., Iwai, M., Wakita, T. & Shimizu, H. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin. Vaccine Immunol. 18, 1889\u20131894, https:\/\/doi.org\/10.1128\/CVI.05225-11 (2011).","journal-title":"Clin. Vaccine Immunol."},{"key":"48534_CR22","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/jmv.24909","volume":"89","author":"S Liu","year":"2017","unstructured":"Liu, S. et al. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J. Med. Virol. 89, 2075\u20132083, https:\/\/doi.org\/10.1002\/jmv.24909 (2017).","journal-title":"J. Med. Virol."},{"key":"48534_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/21645515.2018.1526553","volume":"15","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum Vaccin Immunother 15, 349\u2013357, https:\/\/doi.org\/10.1080\/21645515.2018.1526553 (2019).","journal-title":"Hum Vaccin Immunother"},{"key":"48534_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.2412292","volume":"229","author":"DC Diamond","year":"1985","unstructured":"Diamond, D. C. et al. Antigenic variation and resistance to neutralization in poliovirus type 1. Science 229, 1090\u20131093 (1985).","journal-title":"Science"},{"key":"48534_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/jvi.57.1.81-90.1986","volume":"57","author":"B Blondel","year":"1986","unstructured":"Blondel, B. et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 57, 81\u201390 (1986).","journal-title":"J. Virol."},{"key":"48534_CR26","doi-asserted-by":"publisher","first-page":"12889","DOI":"10.1073\/pnas.1323502111","volume":"111","author":"JF Drexler","year":"2014","unstructured":"Drexler, J. F. et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc. Natl. Acad. Sci. USA 111, 12889\u201312894, https:\/\/doi.org\/10.1073\/pnas.1323502111 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48534-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48534-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48534-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:36:05Z","timestamp":1671280565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48534-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48534"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48534-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11970"}}